Genzyme launches first tests for colon cancer risk:
This article was originally published in Clinica
Executive Summary
Genzyme Genetics has launched two tests in the US designed to screen individuals at increased risk from two types of hereditary colon cancer. The first test detects mutations associated with hereditary nonpolyposis colon cancer (HNPCC), the most common form of hereditary colon cancer which affects between 4,000 and 8,000 people (or between 3% and 6% of all colorectal cancers) each year in the US. The second test is for a mutation associated with adenomatous polyposis coli, a type of colorectal cancer which is particularly prevalent in Ashkenazi Jews. The APCI1307K mutation that the test detects is found in almost 30% of Ashkenazi Jews with a personal and family history of this type of cancer. The new tests will only be available through specialised cancer centres for patients with a family history of these types of cancer.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.